Mikart Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Mikart's estimated annual revenue is currently $39.2M per year.(i)
  • Mikart's estimated revenue per employee is $201,000

Employee Data

  • Mikart has 195 Employees.(i)
  • Mikart grew their employee count by 11% last year.

Mikart's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VP, Product DevelopmentReveal Email/Phone
4
VP MarketingReveal Email/Phone
5
ControllerReveal Email/Phone
6
VP, Quality and RegulatoryReveal Email/Phone
7
Director Engineering and FacilitiesReveal Email/Phone
8
Human Resources DirectorReveal Email/Phone
9
Director, Supply ChainReveal Email/Phone
10
Director Formulation DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$29.7M1488%N/AN/A
#2
$10.5M52-2%N/AN/A
#3
$11.3M564%N/AN/A
#4
$29.1M14521%N/AN/A
#5
$6.8M34-6%N/AN/A
#6
$18.1M90-35%N/AN/A
#7
$48.2M24037%N/AN/A
#8
$1.2M12140%$50MN/A
#9
$12.5M62-9%N/AN/A
#10
$10.1M50-2%N/AN/A
Add Company

What Is Mikart?

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. The company also provides specialty packaging and research support services. A recognized CDMO leader since 1975, Mikart has a wealth of expertise in pharmaceutical development, contract manufacturing and packaging services. Our manufacturing experience includes a broad range of drug compounds, including controlled drug substances.

keywords:N/A

N/A

Total Funding

195

Number of Employees

$39.2M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mikart News

2022-04-19 - Dicyclomine Market Size, Scope And Forecast | Axcan ...

... Lannett, Mutual Pharmaceutical, Mylan, Pioneer Pharmaceuticals, Watson Laboratories, Hikma Pharmaceuticals, Alpharma and Mikart.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$58.2M1961%N/A
#2
$61.9M196-1%N/A
#3
$27.5M197-7%$106M
#4
$30.5M198N/AN/A
#5
$47.9M1988%N/A